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Interferon regulatory factor 5 (IRF5) is widely recognized as a risk locus for systemic lupus
erythematosus (SLE). Risk gene and IRF5 activation is triggered through toll-like receptor
signaling. In myeloid cells, this leads to production of type I interferon and inflammatory
cytokines, with enhanced production in cells of individuals harboring IRF5 risk alleles.
Mouse models have also demonstrated the importance of IRF5 in B cell function, particularly plasma cell differentiation and isotype switching. Here, we evaluated the major SLE
risk haplotype of IRF5 on the functional attributes of freshly isolated B cells from human
subjects who do not have evidence of SLE or other forms of autoimmunity. We took
this approach to avoid the complications of studying genotype-phenotype relationships
in B cells that have been chronically exposed to an inflammatory disease environment
before isolation. We focused on B cell endophenotypes that included gene expression,
antibody secretion, class switching, and apoptotic susceptibility. We performed IRF5
overexpression studies, genetic reporter assays and electro-mobility shift assays on
B and myeloid cell lines. Somewhat surprisingly, the results of our analyses indicate that
IRF5 risk genotypes do not have a B cell intrinsic effect on these B cell functions. By contrast, we confirmed that the IRF5 risk and non-risk haplotypes exert differential effects
in myeloid cells, including an increased susceptibility to apoptosis conferred by the risk
haplotype. We also demonstrated an increased binding of the transcription factor specificity protein 1 to an insertion/deletion present in the risk haplotype. Our findings raise
the specter that genetic risk alleles can have complex and unexpected lineage-specific
effects, and these must be carefully considered when guiding or developing therapies
based on understanding disease risk haplotypes.
Keywords: genetics, B lymphocytes, monocytes, haplotypes, autoimmunity, lupus

INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a breach in B cell tolerance to self-antigens. Genetic, hormonal, and environmental factors contribute to susceptibility to
SLE. The transcription factor interferon regulatory factor 5 (IRF5) is one of approximately 100 genes
with SLE-associated risk variants (1, 2). Within the immune system, IRF5 is expressed in myeloid cells
and lymphocytes (3–5). IRF5 has diverse roles in myeloid cells including production of interferon-α
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levels compared with exon 1a transcripts (29), so the functional
significance of rs2004640 is not entirely clear. The “A” risk allele
of the SNP rs10954213 in the 3′ UTR of exon 9 introduces a
more proximal polyA site. This allele has been shown to confer
increased expression as well as greater mRNA stability likely
due to decreased susceptibility to degradation of the shorter
transcripts (30, 31). The polymorphism rs142738614 is an indel
located 64 bp upstream of exon 1a that refers to the number of
copies of the 5 bp sequence CGGGG; the risk allele has four copies
which introduces an additional binding site for the transcription
factor specificity protein 1 (SP1) (26, 32). To date, the functional
impact of this additional SP1 binding site in predisposition to
SLE is unknown.
Currently, data available on the effects of IRF5 risk alleles in
human B cells are rather limited. In contrast to previous reports,
using cell lines or B cells of SLE patients (2, 33), we demonstrate
that in healthy donors, the IRF5 risk and non-risk haplotypes are
not differentially expressed in B cells in the resting state or after
TLR activation. In addition, IRF5 haplotypes do not differentially
regulate B cell differentiation to antibody-secreting cells (ASCs)
or IRF5-mediated apoptosis, and that IRF5 does not regulate
FcγRIIb expression in human B cells. Our findings confirm that
these same IRF5 risk haplotypes do exert differential effects in
myeloid cells and demonstrate that the 4× CGGGG indel is a
potential causal allele in this context. Thus, we conclude that
IRF5 acts indirectly on B cells through B cell extrinsic pathways.
These data underscore the importance of examining multiple
cell types when studying risk haplotypes in complex diseases.
Moreover, they clearly demonstrate that the observation that a
gene is important in the function of a particular cell type (e.g., the
importance of IR5 in B cell function) does not necessarily imply
that disease-associated haplotypes will display differential effects
intrinsic to that cell type.

(IFNα) and other proinflammatory cytokines (6), regulation of
the cell cycle and apoptosis (7), macrophage polarization (3), and
metabolism (8). IRF5 can be activated by toll-like receptor (TLR)
agonists, including nucleic acid-containing immune complexes
present in SLE. IFNα can contribute to B cell autoreactivity seen
in SLE. Many SLE patients have elevated levels of serum IFNα
and markedly increased expression of interferon-inducible genes
(9–12). Prior studies have shown that SLE-associated risk alleles
of IRF5 display increased expression in myeloid cells and influence monocyte and macrophage activation (8, 13, 14).
IRF5 has direct effects on B cells as well. IRF5 has been shown
to be critical for terminal B cell differentiation to plasma cells
in mice (15, 16). IRF5 also plays a role in isotype switching to
IgG. Irf5−/− mice have increased levels of IgG1 and decreased
levels of IgG2c (17). IRF5 has been shown to directly regulate
transcription of the γ2a locus; Irf5−/− mice do not produce IgG2a
antibodies (18). There is evidence that IRF5 is necessary for SLE
development based on studies of pristane-treated C57BL6 Irf5−/−
and MRL/lpr Irf5−/−mice. The former lack antinuclear antibody
(ANA) titers and glomerular deposits of immune complexes after
pristane challenge (18). The latter survive longer, exhibit milder
glomerulonephritis and lower ANA titers (16, 19) than IRF5 sufficient MRL/lpr mice. Consistent with a contribution of IRF5 to
autoimmunity, and a contribution of lupus-like inflammation to
IRF5 expression, the autoimmune C57BL/6.Nba2, NZB/W, and
Sle123 mouse strains all exhibit increased expression of IRF5 in
splenic cells compared with C57BL/6 mice (20).
FcγRIIb is known to protect against autoantibody production
(21, 22). When bound to IgG immune complexes and co-ligated
to the BCR, FcγRIIb initiates an inhibitory signaling cascade,
mediated through its immunoreceptor tyrosine-based inhibitory
(ITIM) motif (22, 23). In mice, a reciprocal regulation of IRF5 and
FcγRIIb has been reported (20). FcγRIIb is important for B cell
tolerance by setting a cellular activation threshold. C57BL6.Nba2
mice develop a lupus-like phenotype due to the presence of the
Nba2 locus (24). C57BL6.Nba2 Irf5−/− mice exhibit increased
expression of FcγRIIb and C57BL6 Fcgr2b−/− mice exhibit
increased expression of IRF5 (20), suggesting reciprocal regulation of IRF5 and FcγRIIb.
Located on chromosome 7 in humans, IRF5 has a total
of 12 exons. Exons 2–8 and part of 9 are coding. Exon 1 is
subdivided into four non-coding exons 1a–1d (25). Each noncoding exon corresponds to a different promoter (26), allowing
alternative splicing of the gene. There are over 100 known polymorphisms of IRF5, but only four are thought to be functional
(27). Three of these polymorphisms are located in non-coding
regions of IRF5. The non-coding polymorphisms rs142738614,
rs2004640, and rs10954213, are located between exons 1d and
1a, in exon 1b, and in the polyA tail of exon 9, respectively. The
three alleles have been reported to be in linkage disequilibrium
(LD) (13). The fourth polymorphism is a 30 bp insertion/deletion (indel) located in exon 6, and inherited independently of
the three SNPs.
The “T” risk allele of SNP rs2004640 is located in exon 1b
and introduces a donor RNA splice site, enabling expression
of mRNAs containing exon 1b (2). Exon 1b transcripts are
not translated into protein (28) and are expressed at very low
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MATERIALS AND METHODS
Study Subjects and Study Approval

Study participants came from the Genotype and Phenotype
Registry (GAP) registry at the Feinstein Institute. Their ancestry
was European (EUR), African (AFR), Hispanic/Latino, South
Asian (SAS), West Asian, or any combination of these. Subjects
included premenopausal females and age-matched males, from 18
to 50 years of age. All subjects included in the study were homozygous risk or homozygous non-risk for IRF5, without autoimmune
disease and not on corticosteroids, chemotherapeutic or cytotoxic
drugs, or selective cell depletion therapies, thereby allowing us to
study effects of the risk haplotype independent of the effects of disease or medications. The study was approved by the Institutional
Review Board at the Feinstein Institute for Medical Research. Prior
written consent was received from all study participants.

IRF5 Haplotype Assembly

Phase 3 genetic data for the IRF5 locus on chromosome 7 were
extracted from the 1000 Genomes Project browser1 for the
1

2

www.internationalgenome.org (Accessed: July, 2017).
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f ollowing populations: AFR, African; AMR, American/Hispanic/
Latino; EAS, East Asian; EUR, European; SAS, South Asian.
Haplotype maps were constructed for each population using
Haploview software. Genotyping for representative variants (see
Genotyping) was performed on subjects in the GAP.2

(ATCC® TIB-202™) cells were obtained through the American
Type Culture Collection and cultured according to ATCC
recommendations in RPMI supplemented with 10% FBS and
1% penicillin/streptomycin (ThermoFisher Scientific). Primary
B cells and PBMCs were cultured in RPMI supplemented with
10% FBS and 1% penicillin/streptomycin.

Genotyping

We confirmed the LD of rs142738614, rs2004640, and rs10954213
by selecting subjects from the GAP Registry that had been
genotyped for rs2004640 and rs10954213 on the ImmunoChip
(Illumina). The subjects we selected to further genotype for
rs142738614 were homozygous for rs10954213. Genotyping for
rs2004640 and rs10954213 was performed on the ImmunoChip
by the Center for Genomics and Human Genetics at the Feinstein
Institute. For rs142738614 genotyping, genomic DNA was
obtained from 700 subjects homozygous for rs10954213 with
membership in the GAP registry. The genotyping PCR was performed using the AmpliTaq Gold® DNA Polymerase with Buffer
II and MgCl2 kit (ThermoFisher Scientific), dNTPs (Takara),
DMSO (Sigma), and PCR-grade H2O. Primers used for genotyping were as follows: forward 5′ CTGCAGTTGCCAGGTCAGT
3′, reverse 5′ CGGACGCAGAGAGGAGAG 3′. Final concentrations of Taq, dNTPS, DMSO, MgCl2, primers, and DNA were
0.05 U/μl, 0.2 mM, 5%, 1 mM, 0.1 µM, and 0.8 ng/µl, respectively.
The touchdown PCR utilized the following cycling parameters:
95°C for 10 min, 12 cycles of: 94°C for 30 s, 62°C for 30 s (0.5°C
decrease/cycle), 72°C for 1 min, followed by 30 cycles of 94°C for
30 s, 56°C for 30 s, 72°C for 1 min, followed by 1 cycle of 72°C
for 5 min. After the PCR, products were subjected to treatment
with ExoSAP-IT® (Affymetrix) according to the manufacturer’s
instructions. PCR products were then sent to GENEWIZ (South
Plainfield, NJ, USA) for sequencing.

Treatment of B Cells With IRF5-Activating
Agents

Primary B cells were seeded into 96-well plates in culture medium
with final concentrations of 2.5 µM CpG ODN 2006 (Invivogen),
5 µg/ml R848 (Resiquimod, Invivogen), or medium alone. Cells
were incubated at 37°C in a humidified 5% CO2 incubator until
further analysis.

RNA Isolation and cDNA Synthesis

Freshly sorted or treated B cells were pelleted and stored in Trizol
at −80°C until RNA isolation. RNA isolation was performed with
the Direct-Zol RNA Miniprep or Microprep Kit (Zymo Research)
according to the manufacturer’s instructions. Freshly isolated
RNA was reverse transcribed into cDNA using the iScript cDNA
Synthesis Kit (BioRad) according to the manufacturer’s instructions and stored at −20°C.

Quantitative Real-Time PCR

All TaqMan assays were obtained from ThermoFisher Scientific. In
all experiments, mRNA levels were normalized to levels of the endo
genous control HPRT1 (Hs99999909_m1). TaqMan assays used
included IRF5 (Hs00158114_m1), FCGR2B (Hs01634996_s1),
SP1 (Hs00916521_m1), and CD86 (Hs01567026_m1). For IRF5
expression in sorted B cell subsets and monocytes, cDNA was
first subjected to preamplification for HPRT1 and IRF5 using
the TaqMan® PreAmp Master Mix Kit (ThermoFisher Scientific)
according to the manufacturer’s instructions. All qPCR reactions
were set up in 384-well format with master mix consisting of
LightCycler 480 Probes Master (Roche), TaqMan assay, and
sterile PCR-grade H2O, with 1 µl cDNA per reaction well (5 µl
cDNA for PreAmp samples). Reactions were performed in
duplicate. All TaqMan assays were done on a Roche LightCycler
480 using the following cycling parameters: one cycle of 95°C for
10 min, and 45 cycles of 95°C for 20 s followed by 60°C for 40 s.
Analysis of sterile transcripts was done using LightCycler 480
SYBR Green I Master (Roche), sterile PCR-grade H2O, and 1 µl
cDNA per reaction well, in duplicate. SYBR Green assays were
done on a Roche LightCycler 480 using the following cycling
parameters as reported previously (34): one cycle of 95°C for
10 min, and 40 cycles of 94°C for 1 min, 58°C for 1 min, and
72°C for 1 min. A melting curve analysis was also performed
with continuous acquisition starting at 97°C and ending at
40°C. Primer sets for sterile transcripts included HPRT1: forward 5′ TGCAGACTTTGCTTTCCTTGGTCAGG 3, reverse
5′ CCAACACTTCGTGGGGTCCTTTTCA 3′, and germline
IgG: forward 5′ TCCTCTCAGCCAGGACCAA 3, reverse 5′
TCTTGGCATTATGCACCTCC 3′ (34). The final concentration
of primers used was 0.1 µM. For baseline expression experiments,
relative mRNA expression levels were calculated using the ΔCt

Human Peripheral Blood Peripheral Blood
Mononuclear Cell (PBMC) and B Cell
Isolation

Up to 50 ml of peripheral blood was drawn from consenting
subjects in the GAP Registry at the Feinstein Institute for Medical
Research. Blood was collected in heparinized tubes and diluted
1:1 with Hank’s Balanced Salt Solution (HBSS). Diluted blood
was overlaid onto Ficoll-Paque PLUS density gradient media (GE
Healthcare) and centrifuged at 400 × g for 30 min at 25°C with
the brake and acceleration turned off. The buffy coat layer was
isolated, washed with HBSS, and resuspended in staining buffer
[HBSS + 2% heat inactivated fetal bovine serum (FBS) + 1 mM
EDTA]. PBMCs were counted and used for further experiments
or when necessary, B cell isolation was performed with the
EasySep Human B Cell Enrichment Kit (Stemcell Technologies)
or the EasySep Human Naïve B Cell Enrichment Kit according to
the manufacturer’s instructions.

Cell Lines and Primary Cell Culture

Ramos (ATCC® CRL-1596™), Raji (ATCC® CCL-86™), Daudi
(ATCC® CCL-213™), Jurkat (ATCC® TIB-152™), and THP-1
2

www.GAPRegistry.org (Accessed: August, 2013).
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the manufacturer’s instructions. Cells were analyzed on a BD LSR
Fortessa.

method, 2(Ct endogenous control − Ct gene of interest). For experiments involving
treatment of B cells with IRF5 activating agents, relative mRNA
expression levels were calculated using the ΔΔCt method,
2((Ct gene of interest, untreated − Ct endogenous control, untreated) − (Ct gene of interest, treated − Ct
endogenous control, treated))
.

ELISpot Assay

On the fourth day of primary B cell culture, Immunolon® flatbottom 96-well microtiter plates (ThermoFisher Scientific) were
coated with goat antihuman IgM (Southern Biotech) at a final
concentration of 10 µg/ml in HBSS for 1 h at 37°C. Plates were
then washed and blocked with culture medium for 1 h at room
temperature. Live cells were counted via trypan blue exclusion
and seeded as serial 1:2 dilutions in fresh culture medium in the
plate in duplicate. Plates were briefly spun to settle cells to the
bottom and incubated overnight in a 37°C humidified 5% CO2
incubator. Plates were subsequently washed and biotinylated goat
antihuman IgM was added at a final concentration of 1.6 µg/ml.
The plates were incubated for 2 h at 37°C. Plates were washed
again and alkaline phosphatase (AP)-conjugated streptavidin was
added at a dilution of 1:1,000 and incubated for 1 h at 37°C. Plates
were washed and developing solution was added: 1 mg/ml BCIP
(Sigma) in AMP buffer. Color development took place at room
temperature in the dark until spots appeared; plates were then
rinsed with dH2O, dried and counted under a light microscope.

Fluorescence-Activated Cell Sorting

For B cell subset sorting, cryopreserved PBMCs were thawed and
stained with the following monoclonal antibodies for 30 min on
ice in the dark: αIgD-FITC, αCD27-PE, αCD38-PE-Texas Red
(BD Biosciences), αCD10-PE-Cy7, αCD19-APC (BioLegend),
and αCD14-Pacific Blue (BD Biosciences). For sorting of
transfected Raji and Daudi B cells, cells were transfected
with either empty or IRF5 overexpressing vectors with a cyan
fluorescent protein (CFP) overexpressing reporter vector (see
Transient Transfection and IRF5 Overexpression), and 24 h later
prepared for sorting by pelleting and resuspended in staining
buffer. Immediately before sorting, 1 µl propidium iodide (PI)
(ThermoFisher Scientific) was added to the cells. PI negative,
CFP-positive cells were sorted, pelleted, and stored in Trizol at
−80°C. In all experiments, cells were sorted using a BD FACSAria
or BD FACSAria SORP.

Flow Cytometry

ELISA

The monoclonal antibody 2B6 that was used for FcγRIIb staining has been described previously (35). All cell surface staining
conditions took place in staining buffer for 30 min on ice in the
dark. For baseline FcγRIIb expression in B cell subsets, cryopreserved PBMCs from genotyped GAP subjects were thawed
and incubated with the following monoclonal antibody cocktail: αFcγRIIb-AF488 (Macrogenics), αIgD-PE, αCD27-APC,
αCD19-PerCP, αCD38-APC-Cy7, αCD10-PE-Cy7 (BioLegend),
αCD14-Pacific Blue (BD Biosciences), and as a dump gate αCD3
and αCD16, both AF700 conjugated. The fixable viability dye
eFluor506 was included for live/dead discrimination (eBioscience). For analysis of stimulated primary B cells, cells were
incubated with eFluor660 fixable viability dye, αCD19-BV421
(BioLegend) and αFcγRIIb-AF488. For measurement of FcγRIIb
in IRF5 overexpression experiments, cells were incubated with
the fixable viability dye eFluor660 and αFcγRIIb-AF488. Only
CFP+ cells were considered in the analysis. For analysis of
antibody-secreting cultured B cells, on the fourth day of culture
B cells were stained with αCD19-APC-Cy7, αCD27-PE, αCD38PE-Texas Red, αCD86-BV711 (BioLegend), αCD138-BV421
(BioLegend), αIgM-PerCP-Cy5.5 (BioLegend), and αIgG-PeCy7
(BD Biosciences), and viability dye eFluor506. All experimental
data were acquired on a BD LSRII or LSR Fortessa and analyzed
using FlowJo software (Treestar).

The protocol followed for the ELISA was the same as the ELISpot
assay with a few modifications. Costar® 96-well flat-bottom
plates were used (Corning) and blocking was done with 3% FBS.
IgM standards and sample supernatants were also diluted in 3%
FBS and incubated for 1.5 h. The incubation with the secondary
antibody, AP-goat anti human IgM (Southern Biotech) was done
at a dilution of 1:1,000 and lasted for 1 h. The developing solution
consisted of 0.05 M Na2CO3, 0.001 M MgCl2, and phosphatase
substrate (Sigma). Absorbance was measured at 405 nm.

Generation of IRF5- and
CPF-Overexpressing Constructs

We obtained a plasmid expressing both IRF5 (NM_001098629.1)
and CFP (GenBank: KT878729.1) as a fusion protein
(Genecopoeia). Both the IRF5 and CFP ORFs were cloned into
the pmaxCloning™ vector (Lonza) separately. For the cloning
of CFP, a PCR was done on the donor fusion protein plasmid
to introduce HindIII and XhoI sites for more straightforward
cloning. The PCR primers used were as follows: forward 5′
GATAAGCTTTCTTGTACA-AAGTGGTTCG 3′, reverse 5′
CACACTCGAGGTAAAAGGACAGG 3′. The PCR consisted
of 50 ng plasmid DNA, reaction buffer, pfuUltra High-Fidelity
DNA polymerase, dNTP mix, 0.1 µM primers, and PCR-grade
H2O. The reaction buffer, polymerase, and dNTP mix were
taken from the QuikChange II Site-Directed Mutagensis Kit
(Agilent Technologies). Cycling parameters were as follows:
95°C 30 s, 25 cycles of 95°C for 30 s, 55°C for 1 min, and
68°C for 1 min, followed by one cycle of 72°C for 5 min. The
product was purified and restriction digested with XhoI and
HindIII. The pmaxCloning™ vector was also digested with
XhoI and HindIII and dephosphorylated with Antarctic AP
(New England Biolabs). Products were purified and ligated

Apoptosis Assay

Peripheral blood mononuclear cells or were cultured medium
with either vehicle (DMSO) or CPT-11 (Sigma) at concentrations of 50 µM. Cells were incubated for 8 h in a 37°C humidified
5% CO2 incubator. After incubation, cells were stained with
eFluor506 viability dye, αCD19-APC (BioLegend), and αCD14Pacific Blue. Cells were then prepared for analysis using the PE
anti-active caspase 3 apoptosis kit (BD Biosciences) according to
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luciferase vectors (Promega). We digested the promoterless firefly
vector, the non-risk allele plasmid, and the risk allele plasmid
with BglII and HindIII (New England Biolabs), dephosphorylated the donor Firefly vector, and ligated it with either the purified
non-risk or risk allele insert. Ligation products were transformed
into E. coli and selected based on carbenicillin resistance.
Colonies were picked and screened via colony PCR using the
same primers as in Section “Genotyping.” The colony PCR was
done with the same reagents and concentrations as in Section
“Genotyping,” but cycling conditions were as follows: 95°C for
10 min, 40 cycles of 95°C for 20 s, 56°C for 30 s, 72°C for 1 min,
and 1 cycle of 72°C for 5 min. Products were visualized on a 1%
agarose gel. A successful colony was transformed into E. coli,
grown and isolated the same way as described in “Generation of
IRF5 and CPF-overexpressing constructs.” The resulting non-risk
allele Firefly vector and risk allele Firefly vector were confirmed
by sequencing at GENEWIZ with the forward primer used in
Section “Genotyping.” Mutation of the risk allele in the Firefly
vector to a non-SP1 binding site was done with the QuikChange
II Site-Directed Mutagensis Kit according to manufacturer’s
instructions. The mutagenic primers used were as follows: forward 5′ GGGCGGGGCGGTTCCGGGCAC-TGCCC 3′, reverse
5′ GGGCAGTGCCCGGAACCGCCCCGCCC 3′.

with T4 DNA ligase (New England Biolabs). DH5α-TIR E. coli
(ThermoFisher Scientific) were transformed and subject to
kanamycin resistance selection. Resistant colonies were picked
and screened via colony PCR using the same primers and cycling
conditions of: 95°C for 10 min, 30 cycles of 95°C for 20 s, 56°C
for 30 s, 72°C for 1 min, and one cycle of 72°C for 5 min. The
PCR mix consisted of the same reagents at the same concentrations as indicated in Section “Genotyping.” PCR products were
visualized on a 1% agarose gel with SYBR Safe DNA Gel Stain
(ThermoFisher Scientific). A positive colony was further grown
in E. coli and plasmid was isolated using the ZymoPURE™
Plasmid Maxiprep Kit (Zymo Research). Confirmation of
plasmid sequence was done at Genewiz (South Plainfield, NJ,
USA) with the forward and reverse primers. For the cloning
of IRF5, a PCR was also done on the donor fusion protein
plasmid to introduce EcoRI and XhoI sites for more straightforward cloning. The primers used were as follows: forward 5′
TATAGAATTCCCAAG-CTGGCTAGTTAAG 3′, reverse 5′
TATACTCGAGATCGAACCACTTTGTACAAGAAA 3′. The
PCR consisted of 150 ng plasmid DNA, PrimeSTAR® HS DNA
Polymerase with reaction buffer (Takara), 0.25 µM primers,
0.2 mM dNTPS (Takara), and sterile PCR-grade H2O. Cycling
conditions were 30 cycles of 98°C for 10 s, 55°C for 15 s, and 72°C
for 1 min. The product was purified and restriction digested with
XhoI and EcoRI. The pmaxCloning™ vector was also digested
with XhoI and EcoRI. Recipient vector dephosphorylation,
ligation, and transformation, and colony PCR procedures were
the same as done for CFP, but colony PCR primers were as follows: forward 5′ CCTGTGTCAGTGCAAGGTGT 3′, reverse 5′
TTCCCCAAAGCAGA-AGAAGA 3′. Products were also visualized on a 1% agarose gel. A positive colony was grown up and
plasmid DNA isolated the same way as for CFP. Confirmation
of plasmid sequence was done at GENEWIZ (South Plainfield,
NJ, USA) with the forward and reverse primers.

Transient Transfection and IRF5
Overexpression

Raji and Daudi cells were transfected with 4 µg plasmid DNA
using the Amaxa Nucleofector Kit V and 3 µg DNA using the
Amaxa Nucleofector™ Kit L (Lonza), respectively, according to
the manufacturer’s instructions. Half the amount of DNA in each
cotransfection reaction consisted of the CFP reporter vector, and
the resultant amount consisted of either IRF5 overexpression
vector or empty vector. To control for plasmid size, IRF5 overexpression vector or empty vector were transfected in equimolar
amounts. Transfected cells were incubated in culture medium for
24 h at 37°C in a humidified 5% CO2 incubator. For experiments
involving stimulation of transfected cells with IRF5 activating
agents, cells were placed into culture medium with 2.5 µM CpG
or 5 µg/ml R848 immediately after transfection.

Generation of Luciferase Reporter
Constructs

We obtained another plasmid with the non-risk IRF5 promoter
(NM_002200) from Genecopoeia (HPRM19470-PG02). To
obtain the promoter with the risk allele, a PCR was performed on
donor genomic DNA with restriction sites for EcoRI and HindIII
in the product. The primers used were as follows: forward 5′
TCTTGGAATTCCCCTCCTGTTTTCCTTCCCTGCTAT 3′,
reverse 5′ GCCA-ACCTGCCGGGCACT 3′. The reaction used
20 ng DNA and the same reagents and concentrations as the
PCR described in Section “Genotyping,” but final concentrations
of DMSO, MgCl2, and primers were 3.5%, 1.5 mM, and 0.5 µM,
respectively. The cycling conditions were 95°C for 5 min, 38 cycles
of 95°C for 20 s, 63°C for 30 s, 72°C for 1 min, and 1 cycle of 72°C
for 5 min. Both the donor plasmid and PCR product were restriction digested with EcoRI and HindIII; the donor plasmid was
then dephosphorylated, ligated with the product, transformed
into E. coli, grown and isolated the same way as described in
“Generation of IRF5 and CPF-overexpressing constructs.” At
this point we had two plasmids; one with the non-risk allele and
one with the risk allele. We also obtained pGL4.10 promoterless
Firefly and pRL thymidine kinase (TK) promoter-driven Renilla
Frontiers in Immunology | www.frontiersin.org

Luciferase Reporter Gene Assay

The following table illustrates transfection conditions for the
given cell lines:
Cell line

Ramos
Raji
Daudi
Jurkat
THP-1

μg DNA
4
4
3
2
2

Nucleofector™ Cell
Line Kit and program

Ratio
firefly:renilla

Incubation
time (h)

V, O-06
V, M-13
L, A-20
V, X-01
V, V-01

10:1
10:1
10:1
10:1
2:1

16
16
16
16
13

Transfected cells were incubated in culture medium for 24 h at
37°C in a humidified 5% CO2 incubator. After incubation, firefly
and renilla activity was measured using the Dual-Glo® Luciferase
Assay System (Promega) according to the manufacturer’s
instructions. Four independent experiments were done with all
5
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RESULTS

five cell lines comparing the risk and non-risk promoters; three
independent experiments were done with THP-1 cells comparing
the risk, non-risk, and mutated promoters.

Common IRF5 Risk and Non-Risk
Haplotypes Are Present Across Various
Populations

Electro-Mobility Shift and Supershift
Assays

Using the 1000 Genomes Project data (36), we determined haplotype frequencies for the IRF5 locus (Figure 1A) for AFRs, Latino/
Hispanics, EASs, EURs, and SASs Most of the IRF5 variants associated with SLE are in a high degree of LD (Figure 1B). In all populations, the risk variants of rs142738614, rs2004640, rs10954213, and
rs10488631 are inherited together, with the exception of the risk
allele of rs10488631 which is present at a frequency <5% in AFRs
and EASs. Our data show that (1) rs142738614, rs2004640, and
rs10954213 are three suitable markers for determining the presence
of the common risk and non-risk haplotype across populations
and (2) four copies of the CGGGG sequence of the rs142738614
promoter indel is a suitable proxy for the risk haplotype.

Ramos, Raji, Daudi, and THP-1 cells were subcultured at 4 × 105/
ml and harvested when a total of 35 × 106 cells was present (~48 h
later). Nuclear extract was prepared using the NE-PER® Nuclear
and Cytoplasmic Extraction Kit (ThermoFisher Scientific)
according to the manufacturer’s instructions. Infrared (700 nm)
labeled oligonucleotides were obtained from Integrated DNA
Technologies (Coralville, IA, USA). Probe sequences used were
as follows: non-risk 5′ AGTGGATTCGCGGGG-CGGGGCGGG
GCACTGC 3′, risk 5′ AGTGGATTCGCGGGGCGGGGCGGGGC
GGGGCACT-GC 3′. The Odyssey Infrared electro-mobility shift
assay (EMSA) Kit (LI-COR) was used according to the manufacturer’s instructions. For supershift reactions, 1 µg rabbit anti-SP1
or isotype control (Cell Signaling Technology) was used. Gels were
imaged on a LI-COR Infrared Odyssey machine.

IRF5 Expression Is Higher in Monocytes
and IgD− Memory B Cell Subsets
Independent of Haplotype

Statistical Analysis

In SLE, B cell tolerance checkpoints are compromised (37), and
it has been shown that SLE risk alleles can affect those tolerance
checkpoints. To address whether the IRF5 risk haplotype might
affect B cell tolerance, we first asked whether IRF5 expression
differs across B cell subsets and whether the risk and non-risk
haplotypes are differentially regulated as expression quantitative

Statistical analyses were performed with GraphPad Prism 6
software. Statistical significance was determined with the following tests where indicated: Friedman test with Dunn’s multiple
comparison test, Wilcoxon matched-pairs signed rank test,
Mann–Whitney test, and the Kruskal–Wallis test. p Values < 0.05
were considered significant.

FIGURE 1 | Common interferon regulatory factor 5 (IRF5) risk and non-risk haplotypes are present across various populations. (A) Chromosomal location of the
IRF5 locus of interest with SNPs considered in our study. Alleles are indicated as non-risk:risk. (B) Condensed haplotypes obtained from 1000 Genomes present
in >5% of the indicated ethnic populations. Those labeled risk and non-risk were included in our study. Abbreviations: ins, insertion; del, deletion.
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trait loci (eQTL). We compared expression of IRF5 in B cells
alongside expression of IRF5 in monocytes. We sorted monocytes based on expression of CD14 and gated B cells based
on CD19 expression. CD19+ B cells were sorted into four
populations: naïve (IgD+CD27−CD10loCD38lo), transitional
(IgD+CD27−CD10hiCD38hi), and CD27+ memory B cells, both
IgD+CD27+ and IgD−CD27+ (Figure 2A). IRF5 expression was
significantly higher in monocytes than in B cells, and highest in
CD27+IgD− B cells out of all the sorted B cell subsets (Figure 2B).
Whether or not B cells or monocytes were from subjects carrying the risk or non-risk haplotype did not affect gene expression
(Figure 2C). Thus, although IRF5 may play an important role in
class switched, antigen-experienced B cells, the presence of the
IRF5 risk haplotype does not alter gene expression in unstimulated, circulating B cells or unstimulated monocytes.

whether stimulation of B cells through an IRF-dependent
pathway would trigger haplotype-specific expression differences.
B cells were stimulated with the TLR9 and TLR7 agonists, CpG
or R848, respectively, for 5 or 24 h and IRF5 gene expression
was measured. Successful B cell stimulation was confirmed by
increased CD86 expression after 5 h (Figure 3A). We observed
a slight but significant increase in IRF5 expression 5 h after CpG
stimulation as well as a decrease in expression 24 h after CpG
or R848 stimulation (Figure 3B) confirming that IRF5 is within
the TLR7 and 9 pathways. The presence of the IRF5 risk or nonrisk haplotype did not differentially affect the response to TLR
agonists (Figure 3C).

Susceptibility to Apoptosis in B Cells Does
Not Differ According to IRF5 Haplotype

While we observed no significant difference in basal or stimulated levels of expression of IRF5, we thought it important to ask
whether an effect of the IRF5 risk haplotype might be revealed in
a more sensitive bioassay. IRF5 is known to play a critical role in
cell cycle arrest and cell death (7). Irinotecan (CPT-11), a potent
topoisomerase inhibitor and DNA damaging agent, activates an

IRF5 Risk Alleles Do Not Differentially
Affect IRF5 Expression by In Vitro
Stimulated B Cells

The impact of some disease-associated risk haplotypes is seen
only in activated cells as “response eQTLs.” We therefore asked

FIGURE 2 | Interferon regulatory factor 5 (IRF5) expression is higher in monocytes and IgD− memory B cell subsets independent of haplotype. Monocytes and four
subsets of B cells were sorted after gating on CD14+ and CD19+ cells, respectively. (A) Gating strategy for IgD+CD27+, IgD−CD27+, CD27−CD10loCD38l0 (naive),
and CD27−CD10hiCD38hi (transitional) B cells. Sorted cells were subjected to qPCR for IRF5 (B,C), and results are shown combined (B) and separated by haplotype
(C). p < 0.01 by Friedman test with Dunn’s multiple comparisons test (B), p = ns by Mann–Whitney test for each B cell subset (C).
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FIGURE 3 | Interferon regulatory factor 5 (IRF5) risk alleles do not affect induced IRF5 expression in B cells. Purified B cells were stimulated with toll-like receptor
agonists CpG or R848 for the indicated times and subjected to qPCR for CD86 (A) or IRF5 (B,C) IRF5 qPCR. Results are shown combined (B) and separated by
haplotype (C). Unstimulated cell expression values are normalized to 1.0. p < 0.05, p < 0.01, and p < 0.0001 by Friedman test with Dunn’s multiple comparisons
test (A,B), p = ns by Wilcoxon matched-pairs signed rank test for each treatment (C).

IRF5-dependent apoptotic program (38). We asked whether IRF5
haplotypes differentially affect apoptosis induced by CPT-11.
PBMCs from healthy genotyped donors were treated with 50 µM
CPT-11 or vehicle for 8 h and analyzed for the expression of active
caspase 3 by flow cytometry. CPT-11 induced a significant increase
in caspase 3 positive PBMCs (Figure 4A). The effect of CPT-11 on
inducing active caspase 3 was evident in both B cells (CD19+) and
monocytes (CD14+) (Figures 4C,D, top). Interestingly, there was
a haplotype dependent induction of apoptosis in monocytes; risk
haplotype carriers had a higher proportion of cells undergoing
apoptosis than non-risk haplotype carriers (Figures 4B,D, bottom). This haplotype dependent induction of apoptosis was not
evident in B cells (Figures 4B,C, bottom). These findings suggest
that although IRF5 plays a role in apoptosis in multiple cell types,
the SLE risk haplotype enhances IRF5-mediated apoptosis in
monocytes and not in B cells.

We were interested in determining whether IRF5 haplotypes differentially promote class switching and plasma cell differentiation
in human B cells. Naïve B cells were cultured with or without
CpG for 4 days and subjected to multiple functional assays
including ELISpot, ELISA, and flow cytometry. B cell activation
was demonstrated by upregulation of CD86 (Figures 5A,B, left),
but the degree of upregulation did not differ according to haplotype (Figure 5B, right). ELISpot analysis indicated that CpG
induced B cells to differentiate into IgM ASCs (Figure 5C, far
left). We confirmed IgM secretion by ELISA (Figure 5C, center
right). CpG treated cells also exhibited increased surface IgM
(Figure 5D, left and center). In all these analyses, results did not
differ according to IRF5 haplotype (Figure 5C, center left and far
right; Figure 5D, right).
IgG secreting cells or surface IgG+ cells were not detected after
the 4-day culture (data not shown), suggesting CpG alone may
not be sufficient to induce class switching to IgG or that 4-day
cultures are too short term for production of IgG to be evident.
We therefore decided to perform quantitative PCR to measure
the relative abundance of IgG germline mRNA in naïve B cells
cultured with or without CpG for 24 h. Transcription of germline
constant region mRNA is reported to precede isotype switching
(39); the resulting transcripts are not translated into protein and
are therefore termed “sterile transcripts.” We considered that
we might detect these sterile transcripts before we could detect

IRF-Specific B Cell Stimulation Results in
Upregulated CD86 Expression and ASC
Differentiation

Based on murine studies, IRF5 has been shown to play a role in
heavy chain class switch recombination to IgG (17, 18) and in
plasma cell differentiation which requires upregulation of the
transcription factor Blimp1 (15); IRF5 controls Blimp1 expression.
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FIGURE 4 | Susceptibility to apoptosis in B cells does not differ according to interferon regulatory factor 5 haplotype. Fresh peripheral blood mononuclear cells
(PBMCs) were treated with 50 mM CPT-11 for 8 h, stained for CD19, CD14, viability dye, active caspase 3, and analyzed by flow cytometry. (A) Representative
dot plots of vehicle and CPT-11-treated PBMCs. (B) Representative dot plots showing proportions of caspase 3+ B cells (top row) and monocytes (bottom row)
in risk (left column) and non-risk (right column) haplotype subjects. (C) Proportion of apoptotic CD19+ cells shown combined (top) and separated by haplotype
(bottom). (D) Apoptotic CD14+ monocytes shown combined (top) and separated by haplotype (bottom). p < 0.0001 by Wilcoxon matched-pairs signed rank test
[(C,D), top], p = ns by Mann–Whitney test for each treatment [(C), bottom], p < 0.05 by Mann–Whitney test for each treatment [(D), bottom].

IRF5 Does Not Affect FcγRIIb Expression
in B Cells

IgG proteins. Surprisingly, we observed a decrease in abundance
of sterile transcripts (Figure 6) and this decrease was observed
equally in risk and non-risk haplotype B cells, suggesting that
TLR7 and 9 signaling may not be sufficient for class switch recombination. Overall, we found that CpG stimulation upregulates
CD86 and surface IgM on B cells and transforms naïve B cells
into IgM secreting cells, and these effects occur independent of
IRF5 haplotype.
Frontiers in Immunology | www.frontiersin.org

The expression of FcγRIIb on B cells represents an important
B cell tolerance mechanism. Triggering FcγRIIb serves as one
mechanism to limit B cell activation through delivery of inhibitory signals that contribute to regulation of the immune response
(22). SLE patients fail to upregulate FcγRIIb on CD27+ memory
B cells (40). Studies with mouse models suggest the existence of
9
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FIGURE 5 | B cell stimulation results in upregulated CD86 expression and antibody-secreting cell (ASC) differentiation. Naive B cells were cultured for 4 days with or
without CpG and analyzed by flow cytometry. (A) Representative histogram of CD86 expression on untreated (shaded peak) and CpG-treated (black outlined peak)
B cells. (B) CD86 expression on B cells combined (left) and separated by haplotype (right). (C) ELISpot data showing proportion of ASCs combined (far left) and
separated by haplotype (center left) and ELISA data showing IgM secretion by B cells combined (center right) and separated by haplotype (far right).
(D) Representative histogram of surface IgM expressed on untreated (shaded peak) and CpG-treated (black outlined peak) B cells. Flow cytometric results of IgM
expression on B cells combined (center) and separated by haplotype (right). p < 0.001 by Wilcoxon matched-pairs signed rank test [(B), left; (C), far left and center
right; (D), center], p = ns by Mann–Whitney test for each treatment [(B), right; (C), center left and far right; (D), right].

FIGURE 6 | Expression of sterile transcripts in B cells. B cells were cultured for 24 h with or without CpG and subject to qPCR for germline IgG. Results are shown
combined (left) and separated by haplotype (right). p < 0.001 (left) by Wilcoxon matched-pairs signed rank test, p = ns by Mann–Whitney test (right).
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protein (Figure 9B, far right and Figure 9C, bottom center right
and far right) levels. We confirmed an increase in IRF5 mRNA
and protein, but expression of FcγRIIb RNA and protein was
unchanged.
To determine whether stimulation of the transfected cells
was necessary to activate the overexpressed IRF5, transfected
cells were stimulated with CpG or R848 for 24 h and analyzed by
flow cytometry. Activation of overexpressed IRF5 did not affect
FcγRIIb expression (Figure 9D). These findings show that overexpressing or activating IRF5 does not affect FcγRIIb expression
in human B cells.

crosstalk between FcγRIIb and IRF5 with negative regulation of
FcγRllb by IRF5 (20). We asked whether a relationship between
IRF5 and FcγRIIb exists in human B cells, and if the IRF5 risk
haplotype might be associated with a decrease in FcγRllb expression. Expression of FcγRIIb was measured on B cell subsets
from genotyped subjects using flow cytometry. Overall, FcγRIIb
expression was highest on IgD+CD27+ B cells (Figure 7A). IRF5
haplotype did not differentially affect FcγRIIb expression in any
B cell subset (Figure 7B). These results show that the IRF5 risk
haplotype does not affect expression of FcγRIIb on B cells.
We next asked whether IRF-dependent stimulation of B cells
would result in haplotype-specific differences in FcγRIIb expression. B cells were stimulated with CpG or R848 for up to 40 h, and
FcγRIIb transcript and protein expression were measured by qPCR
and flow cytometry, respectively. CpG and R848 stimulation both
resulted in significant decreases in FcγRIIb mRNA expression as
early as 5 h after stimulation (Figure 8A). Surprisingly, protein
expression remained unaffected and increased slightly at 24 and
40 h after R848 stimulation (Figure 8C). Although statistically
significant, the changes in protein we observed in R848 stimulated B cells were very small and it is uncertain whether changes
of this magnitude are enough to affect the biology of B cells. There
were no haplotype-specific effects on mRNA or protein levels
(Figures 8B,D). Considering IRF5 expression is low in B cells, we
next sought to determine whether overexpressing IRF5 in B cells
would have a measureable effect on expression of FcγRIIb. We
hypothesized that overexpressing IRF5 would result in a decrease
in FcγRIIb, similar to the negative regulation seen in mice (20).
First we assessed expression of FcγRIIb in the Ramos, Raji, and
Daudi human B cell lines (Figure 9A). We chose to utilize Raji
and Daudi cells, as both expressed significant levels of FcγRllb.
We cotransfected Raji and Daudi cells with a CFP reporter plasmid and either an IRF5 or empty (mock) plasmid. We isolated
CFP+ cells (Figure 9B, center left) and analyzed IRF5 transcript
(Figure 9C, top center left and far left) and protein (Figure 9B,
center right and Figure 9C, top center right and far right) and
FcγRIIb transcript (Figure 9C, bottom center left and far left) and

The IRF5 Promoter Risk indel Results
in Increased SP1 Binding and IRF5
Transcription in Myeloid Cells

We decided to assess the strength of the IRF5 promoter containing either three or four repeats of the 5 bp CGGGG sequence in
various cell lines: myeloid, T cell, and B cell lines. Previous work
has shown increased IRF5 expression with the risk indel in ex vivo
PBMCs and in HEK293 cells using a minigene assay (32). We created two Firefly luciferase reporter plasmids; one with the three
repeats of CGGGG and one with four repeats, and used a normalizing Renilla luciferase plasmid under control of the constitutive
HSV-TK promoter. Ramos, Raji, Daudi, Jurkat, and THP-1 cells
were transfected and analyzed for relative luciferase light units
(Figure 10A, left). The basal level of IRF5 transcription is highest
in THP-1 cells. The fold change in IRF5 transcription was also
highest in THP-1 cells, as was induction of IRF5 transcription
(Figure 10A, center).
Four repeats of the 5 bp CGGGG sequence in the risk haplotype introduce another binding site for the transcription factor
SP1 (32). We asked whether SP1 binding to this additional site
has a role in increased transcription of IRF5. To this end, we
created an additional 4× indel IRF5 promoter-Firefly luciferase
plasmid, with one SP1 binding site mutated to a non-SP1 binding
site. We transfected THP-1 cells with the mutated plasmid and

FIGURE 7 | Interferon regulatory factor 5 risk alleles do no affect baseline FcγRIIb expression in B cell subsets. B cell subsets were analyzed similarly as in Figure 1.
(A) Flow cytometric results of FcγRIIb protein expression in combined B cell subsets and (B) separated by haplotype. p < 0.05 and p < 0.0001 by Friedman test
with Dunn’s multiple comparisons test (A), p = ns by Mann–Whitney test for each B cell subset (B).
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We next decided to assess binding of nuclear transcription
factors from B cell lines and THP-1 cells to the 3× and 4× indel.
Cell lysates were incubated with infrared-labeled oligonucleotides containing three or four repeats of CGGGG and analyzed
by EMSA. A specific band was observed when the 4× indel was
incubated with THP-1 nuclear extracts compared with extracts of
the B cell lines (Figure 10B, left). The banding pattern was also
present in Raji extract with the 4× indel, albeit very faintly. To ask
whether the binding pattern observed in THP-1 cells was due to

compared the results to the 3× and 4× indel promoter reporter
plasmids. We hypothesized that if SP1 were important for the
observed increased IRF5 transcription seen with the 4× indel,
abolishing the additional binding site would result in luciferase
readings similar to those obtained with the 3× promoter reporter
plasmid. Interestingly, this result was obtained in THP-1 cells
(Figure 10A, right). Thus, the SP1 transcription factor has a role
in the increased transcription of the IRF5 risk haplotype observed
in myeloid cells.

FIGURE 8 | Continued
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FIGURE 8 | Interferon regulatory factor 5 activation does not affect FcγRIIb expression in B cells. (A,B) FcγRIIb mRNA expression in B cells treated with CpG (right)
or R848 (left) for the indicated times. Results are combined (A) and separated by haplotype (B). (C,D) FcγRIIb protein expression in B cells treated with CpG (right)
or R848 (left) for the indicated time. Results are combined (C) and separated by haplotype (D). All unstimulated cell expression values are normalized to 1.0. p < 0.05,
p < 0.01, p < 0.001, and p < 0.0001 by Friedman test with Dunn’s multiple comparisons test (A,C), p = ns by Mann–Whitney test for each treatment (B,D).

SP1 (Figure 10C) mRNA levels were higher in THP-1 cells than
in B cell lines. The data suggest that the differential expression of
SP1 in monocytes and B cells is responsible for the haplotypespecific increased expression of IRF5 observed in myeloid cells
and not in B cells.

SP1, we performed a supershift EMSA with anti-SP1 antibody.
Interestingly, we observed a change in the pattern when cell
lysates were incubated with anti-SP1 (Figure 10B, right). We then
asked if this is due to higher IRF5 and SP1 expression in THP-1
cells compared with B cell lines. We observed that both IRF5 and
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FIGURE 9 | Interferon regulatory factor 5 (IRF5) overexpression does not affect FcγRIIb expression in Raji and Daudi cells. (A) FcγRIIb expression in Ramos, Raji,
and Daudi cells. (B) Representative flow cytometric data showing untransfected (far left) and transfected (center left) cells. Gated cells were used for sorting and
analyses. Representative histogram of IRF5 protein expression on mock (red) and IRF5 (blue) transfected cells (center right), representative histogram of FcγRIIb
protein expression on mock (red) and IRF5 (blue) transfected cells (far right). (C) IRF5 mRNA (top row, far left and left) and protein (top row, far right and right) levels
in CFP+ cells. FcγRIIb mRNA (bottom row, far left and left) and protein (bottom row, far right and right) levels in CFP+ cells. (D) FcγRIIb protein levels in CFP+ cells
stimulated with CpG or R848 for 24 h. All data shown are representative of three independent experiments.

and (5) the transcription factor SP1 binds more strongly to the
4× CGGGG indel in myeloid cells and not in B cells. Collectively,
our findings suggest that genetic risk haplotypes need to be
understood in the context of cell lineage-specific functionality.
Thus, somewhat unexpectedly, in the case of B cells and based on
our assays cell intrinsic effects of IRF5 haplotypes do not appear
to be an important factor in risk for SLE. This, of course, does
not rule out cell intrinsic effects that we have not studied and cell
extrinsic effects of IRF5 haplotypes on B cell function, mediated
perhaps through myeloid cell lineages (42).
We note that the literature provides some evidence that
contrasts with our findings. In particular, the original definition
of the IRF5 haplotypic diversity by Graham et al. showed that
SLE risk alleles regulate expression of IRF5 in B lymphoblastoid
cell lines. This was most clearly demonstrated for the rs10954213
allele that also regulates the formation of the short and long forms

DISCUSSION
Approximately 100 genes have been identified in GWAS of SLE
(41); however, the functionality of the majority of the risk alleles
has not been elucidated. The goal of this study was to define an
SLE-associated IRF5 risk haplotype and determine the effects
of the risk haplotype on the biology of B cells. We first defined
a risk haplotype common to various populations that included
the 4× CGGGG indel in the promoter region and two risk SNPs,
rs10954213 and rs2004640. Our major findings were (1) the
IRF5 risk haplotype does not affect quantitative IRF5 expression
in resting or activated B cells, (2) IRF5 activation triggers CD86
upregulation and differentiates B cells into IgM ASCs, but this
is not influenced by IRF5 haplotype, (3) IRF5 does not regulate
FcγRIIb in human B cells, (4) the IRF5 risk haplotype differentially
affects IRF5-mediated apoptosis in monocytes and not in B cells,
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FIGURE 10 | The interferon regulatory factor 5 (IRF5) promoter risk insertion/deletion (indel) results in increased IRF5 transcription and specificity protein 1 (SP1)
binding in myeloid cells. (A) Normalized activities of non-risk and risk indel promoter-driven luciferase transcription in various cell lines (left), fold change in luciferase
activity due to the risk indel in various cell lines (center), and risk, non-risk, and mutated promoter-driven luciferase transcription in THP-1 cells (right). Results of three
or four independent experiments are shown. (B) Electrophoretic mobility shift assay showing binding to the 3× and 4× CGGGG indel by various nuclear extracts
(left), supershift assay showing SP1 binding to the 3× and 4× CGGGG indel in nuclear extracts of THP-1 cells (right). Results of three independent experiments
are shown. (C) SP1 mRNA levels in various cell lines. Results of three independent experiments are shown. p < 0.05 by Kruskal–Wallis test [(A), center].

of the polyA tail of IRF5. Overall gene expression was assessed
with Northern blot analysis or using microarray data in public
databases, whereas our studies have utilized a TaqMan assay
that is directed to the exon 2–3 boundary. Thus, it is possible
that these two approaches may give different results in terms
of overall quantitation of message due to differences in mRNA
isoforms. Our approach to mRNA quantitation may have missed
quantitative differences in the various mRNA splice variants that
are encoded the risk and non-risk haplotypes. It is also possible
that B cell lines have regulatory mechanisms that differ from
native B cell populations. Nevertheless, our data strongly suggest
that if mRNA splicing differences do exist between the risk and
non-risk haplotypes, they do not substantially affect the B cell
functional assays we have described here. Therefore, regardless of
the mechanism, differences in haplotype transcriptional patterns
do not appear to have a cell intrinsic effect on the critical B cell
functions that we have investigated. It may well be that transcript
isoforms do play some role in B cell functions that we have not
examined, but our data address the major mechanisms that have
been reported to be associated with B cell abnormalities in lupus.
These data emphasize the level of complexity that must be
considered when trying to understand gene association studies
with disease related phenotypes, namely that a gene may serve
a critical purpose in a particular cell type, but a risk haplotype
may or may not function differently from the non-risk haplotype
in that cell type. The chain of causation in autoimmune diseases
Frontiers in Immunology | www.frontiersin.org

such as SLE clearly involves complex cell-cell interactions. The
data reported here strongly suggest that the influence of IRF5
on B cell abnormalities is likely to depend to a large degree on
the effects of IRF5 on cells which have a regulatory role on B cell
function, such as myeloid cells. Further functional studies of IRF5
can profitably be focused on this possibility.
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